Title: Epratuzumab
CAS Registry Number: 205923-57-5; 501423-23-0 (90Y-labeled form)
CAS Name: Anti-(human CD22 (antigen)) immunoglobulin G1 (human-mouse monoclonal IMMU-hLL2 g-chain) disulfide with human-mouse monoclonal IMMU-hLL2 k-chain dimer
Additional Names: hLL2
Manufacturers' Codes: AMG-412; IMMU-hLL2
Trademarks: LymphoCide (Immunomedics)
Literature References: Humanized monoclonal antibody directed against CD22, a transmembrane sialoglycoprotein expressed on the surface of B-cell malignancies. Prepn: S.-O. Leung, H. Hansen, WO 9604925; eidem, US 5789554 (1996, 1998 both to Immunomedics); idem et al., Mol. Immunol. 32, 1413 (1995). Characterization and binding study: J. Carnahan et al., Clin. Cancer Res. 9, Suppl., 3982s (2003). Clinical pharmacokinetics and evaluation in non-Hodgkin's lymphoma: J. P. Leonard et al., Clin. Cancer Res. 10, 5327 (2004). Review of clinical development: A. B. Siegel et al., Semin. Oncol. 30, 457-464 (2003).
Derivative Type: 90Y Epratuzumab Tetraxetan
CAS Registry Number: 501423-25-2
Additional Names: 90Y-DOTA-hLL2
Literature References: Prepn and biodistribution studies: S. V. Govindan et al, Bioconj. Chem. 9, 773 (1998); G. L. Griffiths et al., J. Nucl. Med. 44, 77 (2003). Clinical pharmacokinetics and efficacy: R. M. Sharkey et al., ibid. 2000. Clinical evaluation in non-Hodgkin's lymphoma: O. Lindén et al., Clin. Cancer Res. 11, 5215 (2005).
Therap-Cat: Antineoplastic. 90Y-labeled form in radioimmunotherapy.
Keywords: Antineoplastic; Monoclonal Antibodies.
Eprazinone Eprinomectin Epristeride Eprosartan Eprozinol

Epratuzumab ?
Monoclonal antibody
Type Whole antibody
Source Humanized (from mouse)
Target CD22
Clinical data
Trade names LymphoCide
Legal status Investigational
CAS number 205923-57-5 N
ATC code None
PubChem SID47206001
DrugBank DB04958
UNII 3062P60MH9 YesY
KEGG D04036 YesY
Chemical data
Formula  ?
 N (what is this?)  (verify)

Epratuzumab (planned trade name LymphoCide) is a humanized monoclonal antibody. Potential uses may be found in oncology and in treatment of inflammatory autoimmune disorders, such as systemic lupus erythematosus (SLE).[1][2] The manufacturers in August 2009 announced success in early trials against SLE,[3] and the drug is in Phase III clinical trials as of February 2014.[4]